文献速递冠心病

皮下注射selatogrel抑制急性心肌梗死患者血小板聚集

Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

本研究纳入47例急性心肌梗死患者,随机接受皮下注射selatogrel 8 mg或16 mg,主要终点为给药后30分钟治疗反应率(P2Y12反应单位<100)。8 mg和16 mg组30分钟反应率分别为91%和96%,15分钟反应率分别为75%和91%,60分钟持续。药物耐受良好,无大出血并发症。

要点

  • 皮下selatogrel在AMI患者中30分钟即达高反应率,8 mg为91%,16 mg为96%。
  • 反应率与AMI类型、年龄、性别无关,15分钟起效并持续至60分钟。
  • 单次皮下selatogrel耐受良好,未发生大出血并发症。

核心结论

  • 单次皮下注射selatogrel在AMI患者中安全,并诱导深刻、快速且剂量相关的抗血小板反应。

研究设计与样本

  • 随机、开放标签研究,47例AMI患者随机接受单次皮下selatogrel 8 mg(n=24)或16 mg(n=23),随后接受替格瑞洛(n=43)或氯吡格雷(n=1)。
  • 主要终点为给药后30分钟治疗反应(P2Y12反应单位<100,VerifyNow检测),安全性评估至注射后48小时。

主要发现

  • 30分钟反应率:8 mg组91%(单侧97.5%CI 80%–100%),16 mg组96%(97.5%CI 87%–100%);对>85%目标值的P值分别为0.142和0.009。
  • 15分钟反应率:8 mg组75%(97.5%CI 58%–100%),16 mg组91%(97.5%CI 80%–100%);60分钟反应率:8 mg组75%(97.5%CI 58%–100%),16 mg组96%(97.5%CI 87%–100%)。
  • 15分钟时P2Y12反应单位中位数:8 mg组51(范围4–208),16 mg组9(范围2–175)。
  • 反应率与AMI表现类型、年龄或性别无关。
  • selatogrel耐受良好,无大出血并发症。

关键数值与推荐

  • 治疗反应定义为P2Y12反应单位<100(VerifyNow检测)。
  • 8 mg组30分钟反应率91%(97.5%CI 80%–100%),16 mg组96%(97.5%CI 87%–100%)。
  • 15分钟反应率8 mg组75%(97.5%CI 58%–100%),16 mg组91%(97.5%CI 80%–100%)。
  • 60分钟反应率8 mg组75%(97.5%CI 58%–100%),16 mg组96%(97.5%CI 87%–100%)。

临床怎么用

  • 对于AMI患者,皮下注射selatogrel 8 mg或16 mg可在30分钟内提供快速、高比例的血小板抑制,且安全性良好。
  • 该给药方式可能为口服P2Y12抑制剂起效延迟的AMI患者提供替代或桥接策略。

局限性

  • 研究样本量较小(47例),且为开放标签设计。
  • 随后接受替格瑞洛或氯吡格雷治疗可能影响后续血小板抑制评估。
  • 安全性评估仅至注射后48小时,长期安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral P2Y12 receptor antagonists exhibit delayed onset of platelet inhibition in patients with acute myocardial infarction (AMI). Selatogrel is a potent, highly selective, and reversible P2Y12 receptor antagonist with a rapid onset and short duration of action. OBJECTIVES: This study sought to assess inhibition of platelet aggregation following subcutaneous administration of selatogrel in patients with AMI. METHODS: Patients with AMI were randomized to a single subcutaneous dose of selatogrel of 8 or 16 mg. The primary endpoint was response to treatment (P2Y12 reaction units <100; measured by VerifyNow) at 30 min post-dose. Safety was assessed up to 48 h post-injection. RESULTS: Forty-seven patients received selatogrel 8 mg (n = 24) or 16 mg (n = 23) followed by ticagrelor (n = 43) or clopidogrel (n = 1). The proportion of responders 30 min post-dose was 91% (one-sided 97.5% confidence interval [CI]: 80% to 100%) and 96% (97.5% CI: 87% to 100%) with 8 and 16 mg, respectively (p values for responders >85% target; p = 0.142 and p = 0.009, respectively). Response rates were independent from type of AMI presentation, age, or sex. A similar response rate was observed at 15 min (8 mg: 75% [97.5% CI: 58% to 100%]; 16 mg: 91% [97.5% CI: 80% to 100%]), which was sustained at 60 min post-dose (8 mg: 75% [97.5% CI: 58% to 100%]; 16 mg: 96% [97.5% CI: 87% to 100%]). At 15 min, median P2Y12 reaction units was 51 (range: 4 to 208) for 8 mg and 9 (range: 2 to 175) for 16 mg. Selatogrel was well tolerated, without major bleeding complications. CONCLUSIONS: Single-dose subcutaneous administration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-related antiplatelet response. (A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack; NCT03487445, 2018-000765-36 [EudraCT]).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sinnaeve P, Fahrni G, Schelfaut D, et al. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2020. PMID: 32439008. doi:10.1016/j.jacc.2020.03.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。